SHANGHAI, Aug. 18, 2022 /PRNewswire/ — Henlius (2696.HK) announced its 2022 interim results. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched in…

Generated by Feedzy